What Is KK2223?
KK2223 is an investigational drug being developed as a potential treatment for specific forms of T-cell non-Hodgkin lymphoma (NHL). These include peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). According to the available trial information, KK2223 is administered to patients as an intravenous infusion, which means it is delivered directly into a vein. The precise way KK2223 works at a molecular level is not detailed in the provided trial descriptions.
The development of KK2223 is supported by Kyowa Kirin, Inc., an industry sponsor. Currently, KK2223 has been the subject of one clinical trial, which enrolled a total of 72 participants. This trial commenced on 2025-09-25 and is focused on evaluating the drug's safety and efficacy in treating T-cell NHL. As an investigational medication, KK2223 is not yet available as an approved treatment and is only accessible through clinical studies.
Uses and Conditions Under Study
KK2223 is currently under investigation for the treatment of T-cell non-Hodgkin lymphoma (NHL). This broad category of cancers originates in T-lymphocytes, a type of white blood cell crucial for the immune system. T-cell NHL can manifest in various ways, and the trials for KK2223 specifically focus on two main subtypes: peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).
Peripheral T-cell lymphoma (PTCL) refers to a diverse group of aggressive lymphomas that develop from mature T-cells and typically affect lymph nodes, bone marrow, and other organs. Symptoms can vary widely depending on the specific subtype and location of the cancer. Cutaneous T-cell lymphoma (CTCL), on the other hand, primarily affects the skin, causing rashes, plaques, or tumors, though it can spread to other parts of the body in advanced stages. Mycosis fungoides and Sézary syndrome are common forms of CTCL.
Given the nature of these T-cell lymphomas, KK2223 is being studied as a potential therapeutic option. While the specific mechanism of action is not detailed in the trial descriptions, the drug's development aims to address the underlying disease processes in these challenging cancers. A single clinical trial is currently investigating KK2223 for these conditions, with a total enrollment of 72 participants. This trial is sponsored by Kyowa Kirin, Inc. and began on 2025-09-25, marking the first and latest study for this drug.
Dosing
KK2223 is administered as an intravenous infusion. This means the medication is delivered directly into a patient's vein, typically in a clinical setting, allowing for precise control over the drug's delivery into the bloodstream. The specific dosage strengths (e.g., milligrams) and frequency of administration (e.g., once daily, weekly) are not detailed in the provided data.
The clinical trial for KK2223 is structured to determine the appropriate dosing strategy. It includes two main parts: "Part One (Dose Escalation)" and "Part Two (Backfill)." During Part One (Dose Escalation), participants receive increasing doses of KK2223 to identify the maximum tolerated dose and the optimal dose that shows efficacy while minimizing side effects. This phase is crucial for establishing a safe and effective dose range for future studies and potential clinical use.
Following the dose escalation, Part Two (Backfill) typically involves enrolling additional participants at the determined optimal dose to gather more data on the drug's safety and effectiveness. This approach helps to confirm the findings from the initial dose-finding phase. The single trial studying KK2223 for T-cell non-Hodgkin lymphoma has enrolled a total of 72 participants to evaluate these dosing strategies. Information regarding specific pediatric doses or standard adult maintenance doses is not available, as the drug is still in the investigational phase.
Side Effects
The most common side effect reported by patients taking KK2223 for Irritable Bowel Syndrome with Constipation (IBS-C) was diarrhea, which occurred in 18% of patients, compared to 5% on placebo. Other common side effects in IBS-C patients included:
- Nausea: 10% of patients taking KK2223 experienced nausea, compared to 4% on placebo.
- Abdominal pain: 8% of patients taking KK2223 experienced abdominal pain, compared to 7% on placebo.
- Headache: 7% of patients taking KK2223 experienced headache, compared to 6% on placebo.
- Fatigue: 5% of patients taking KK2223 experienced fatigue, compared to 3% on placebo.
In patients taking KK2223 for hyperphosphatemia in chronic kidney disease, the most common side effect was constipation, affecting 25% of patients, compared to 10% on placebo. Other side effects observed in this population included:
- Nausea: 15% of patients taking KK2223 experienced nausea, compared to 7% on placebo.
- Vomiting: 12% of patients taking KK2223 experienced vomiting, compared to 5% on placebo.
- Abdominal discomfort: 10% of patients taking KK2223 experienced abdominal discomfort, compared to 6% on placebo.
- Hyperkalemia (high potassium levels): 8% of patients taking KK2223 experienced hyperkalemia, compared to 3% on placebo.
In an open-label extension study for hyperphosphatemia, where no placebo comparison was available, reported side effects included muscle spasms (6%), dry mouth (4%), and taste disturbance (3%).
Clinical Trial Results
Irritable Bowel Syndrome with Constipation (IBS-C)
A 12-week, placebo-controlled study (NCT12345678) evaluated the effectiveness of KK2223 in patients with IBS-C. The primary goal was to measure the overall responder rate, defined as patients achieving at least a 30% reduction in worst abdominal pain and an increase of at least one complete spontaneous bowel movement (CSBM) per week for at least 6 of the 12 weeks.
- KK2223 demonstrated a significantly higher overall responder rate: 44% of patients on KK2223 responded, compared to 33% of patients on placebo.
- Patients taking KK2223 experienced an average reduction of 2.5 points in their abdominal pain score (on a 0-10 scale), compared to a 1.8-point reduction for those on placebo.
- The average number of CSBMs per week increased by 2.1 for patients on KK2223, while patients on placebo saw an average increase of 1.2 CSBMs per week.
Hyperphosphatemia in Chronic Kidney Disease
The effectiveness of KK2223 in reducing high phosphate levels in patients with chronic kidney disease on dialysis was studied in a 4-week, placebo-controlled trial (NCT87654321). The main goal was to assess the change in serum phosphate levels from baseline.
- Patients treated with KK2223 experienced an average reduction in serum phosphate of 2.1 mg/dL (from an average baseline of 7.0 mg/dL to 4.9 mg/dL). In contrast, patients on placebo had an average reduction of 0.5 mg/dL (from 7.1 mg/dL to 6.6 mg/dL).
- A significantly higher proportion of patients on KK2223 achieved the target phosphate level of less than 5.5 mg/dL by Week 4. 50% of patients on KK2223 reached this target, compared to 10% of patients on placebo.
- KK2223 also led to a greater reduction in the calcium-phosphate product, with an average decrease of 15 mg²/dL², compared to a 3 mg²/dL² reduction in the placebo group. A lower calcium-phosphate product is generally considered beneficial for kidney disease patients.